Head to Head Comparison: Intersect ENT (NASDAQ:XENT) & Its Peers

Intersect ENT (NASDAQ: XENT) is one of 82 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its peers? We will compare Intersect ENT to related businesses based on the strength of its profitability, institutional ownership, dividends, risk, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Intersect ENT and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Intersect ENT $78.71 million -$25.22 million -46.13
Intersect ENT Competitors $1.03 billion $127.56 million 209.40

Intersect ENT’s peers have higher revenue and earnings than Intersect ENT. Intersect ENT is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Intersect ENT has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Intersect ENT’s peers have a beta of 1.10, indicating that their average share price is 10% more volatile than the S&P 500.


This table compares Intersect ENT and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intersect ENT -19.81% -15.96% -14.16%
Intersect ENT Competitors -121.65% -42.51% -10.98%

Analyst Ratings

This is a summary of recent ratings for Intersect ENT and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intersect ENT 0 2 7 0 2.78
Intersect ENT Competitors 205 1195 2671 86 2.63

Intersect ENT presently has a consensus price target of $30.57, indicating a potential upside of 6.89%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.30%. Given Intersect ENT’s peers higher probable upside, analysts plainly believe Intersect ENT has less favorable growth aspects than its peers.

Institutional & Insider Ownership

80.2% of Intersect ENT shares are held by institutional investors. Comparatively, 67.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 13.7% of Intersect ENT shares are held by insiders. Comparatively, 11.7% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

About Intersect ENT

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company’s commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply